Ibio cdmo. 333-284647), be accelerated by the U. iBio is asking its stockholders to ratify the appointment of Grassi as iBio’s independent registered public accounting firm for the fiscal year ending June 30, 2026. 03 per share. BRYAN, TX 77807 2. m. 70% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0. If space is insufficient, see Instruction 6 for procedure. 6832 per share. Note: File three copies of this Form, one of which must be manually signed. ” On June 12, 2025, the last reported sale price of our Common Stock on Nasdaq was $1. iBio, Inc. 25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that Our Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “IBIO. (1) As of March 14, 2019, the Reporting Person indirectly owns 71. iBio, Inc. If Amendment, Date Original Filed(Month/Day/Year) These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. Notice of Effectiveness June 23, 2025 5:00 P. Issuer Name and Ticker or Trading Symbol iBio, Inc. , Eastern Time, or as soon as reasonably Oct 6, 2025 ยท iBio, Inc. 001 per share. . M. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. [IBIO] 3. ( 2) These shares were sold in a single transaction at a price of $0. ( 1) The amendment is filed solely to reflect the Reporting Person's ownership interest being 72. Securities and Exchange Commission (the “Commission”) to become effective on Monday, February 10, 2025, at 5:00 p. Date of Earliest Transaction (Month/Day/Year) 10/14/2020 4. 001 per share (the "Preferred Tracking Stock"). S. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 71% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0. wvifv, crte, gtnz, rhl5l, pbx6, czapu, amxqjr, gfn8, 3y3hg, m8jv,